IL5 and eosinophilic esophagitis: Mepolizumab (anti-IL-5) and anti-IL-13 neutralization therapy have been shown to reduce esophageal eosinophilia [33,34], but neither anti-IL-5 nor anti-IL-13 therapy can completely restrict EoE pathogenesis in humans.